Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT06234306
Recruiting Observational

Molecularly Redefining Small Bowel Adenocarcinoma to Accelerate Precision Patient Care

NCT06234306 · tracked via the Priya Life Science Denmark tracker
Sponsor
Copenhagen University Hospital at Herlev
Phase
Observational
Started
2024-01-01
Last updated
2024-01-31

Condition(s) studied

Small Bowel Adenocarcinoma

Study summary

Small bowel adenocarcinoma is a rare malignancy, and there is limited knowledge about its optimal clinical management and molecular background. The SBAMOL study is an observational biomarker study that aims to identify prognostic and predictive biomarkers. This effort is intended to lay the groundwork for personalized medicine tailored to this specific patient group.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion criteria: Patients with histologically verified small bowel adenocarcinoma Patients older than 18 years Exclusion criteria: Insufficient material for molecular testing Patients registered in Vævsanvendelsesregistret\& Vævsanvendelsesregistret; refers to a central Danish registry where patients can opt out of allowing their biological material to be used for purposes other than their own disease management.

Primary outcome measure(s)

  • Molecular characterization of patients with SBA using high-throughput DNA-, mRNA- and T-cell receptor sequencing and targeted protein expression analyses. — 5 years
    Due to the scarce knowledge of the biological background of SBA. The primary endpoint of the study is to present a comprehensive descriptive molecular characterisation of patients with SBA.

Trial sites (3)

FacilityCityRegionStatus
Department of Oncology, Aarhus University Hospital Aarhus N Denmark Recruiting
Department Surgical Gastroenterology, Copenhagen University Hospital - Rigshospitalet Copenhagen Ø Denmark Recruiting
Department of Oncology Copenhagen University Hospital - Herlev and Gentofte Herlev Denmark Recruiting

More Copenhagen University Hospital at Herlev trials in Denmark

High Impact Training to Patients with Prostate Cancer and Bone Metastases Recruiting
Benefit of Spectral Information in Patients Suspected for Lung Cancer Recruiting
Danish Precocious Puberty Study - DAPP Study A National Cohort Study on Incidence and Etiologies for Precocious Puberty Starting soon
Rapid Response Home Care as an Alternative to Acute Admission Active, not recruiting
Clinical Assessment and Treatment in the Nursing Home as an Alternative to Hospital Admission Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06234306 on ClinicalTrials.gov ↗ ← All trials in Denmark